200 related articles for article (PubMed ID: 18642399)
21. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
22. HIV-1-specific RNA interference.
Boden D; Pusch O; Ramratnam B
Curr Opin Mol Ther; 2004 Aug; 6(4):373-80. PubMed ID: 15468596
[TBL] [Abstract][Full Text] [Related]
23. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS.
Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G
Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
Li Y; Starr SE; Lisziewicz J; Ho WZ
Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
[TBL] [Abstract][Full Text] [Related]
25. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
26. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of HIV replication: a powerful antiviral strategy by IFN-beta gene delivery in CD4+ cells.
Brule F; Khatissian E; Benani A; Bodeux A; Montagnier L; Piette J; Lauret E; Ravet E
Biochem Pharmacol; 2007 Sep; 74(6):898-910. PubMed ID: 17662695
[TBL] [Abstract][Full Text] [Related]
28. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus.
Vandekerckhove L; Christ F; Van Maele B; De Rijck J; Gijsbers R; Van den Haute C; Witvrouw M; Debyser Z
J Virol; 2006 Feb; 80(4):1886-96. PubMed ID: 16439544
[TBL] [Abstract][Full Text] [Related]
29. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
Li M; Li H; Rossi JJ
Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937
[TBL] [Abstract][Full Text] [Related]
30. Lentiviral vector engineering for anti-HIV RNAi gene therapy.
ter Brake O; Westerink JT; Berkhout B
Methods Mol Biol; 2010; 614():201-13. PubMed ID: 20225046
[TBL] [Abstract][Full Text] [Related]
31. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
Anderson J; Akkina R
Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for HIV infection.
Morgan RA
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():41-4. PubMed ID: 9020935
[TBL] [Abstract][Full Text] [Related]
33. Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs.
von Eije KJ; ter Brake O; Berkhout B
J Gene Med; 2009 Jun; 11(6):459-67. PubMed ID: 19384894
[TBL] [Abstract][Full Text] [Related]
34. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis.
Hnatyszyn H; Spruill G; Young A; Seivright R; Kraus G
Gene Ther; 2001 Dec; 8(24):1863-71. PubMed ID: 11821940
[TBL] [Abstract][Full Text] [Related]
35. Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule.
Cagnon L; Cucchiarini M; Lefebvre JC; Doglio A
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(4):349-58. PubMed ID: 7541291
[TBL] [Abstract][Full Text] [Related]
36. Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.
Leonard JN; Schaffer DV
J Virol; 2005 Feb; 79(3):1645-54. PubMed ID: 15650190
[TBL] [Abstract][Full Text] [Related]
37. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
38. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
[TBL] [Abstract][Full Text] [Related]
39. Progress towards gene therapy for HIV infection.
Yu M; Poeschla E; Wong-Staal F
Gene Ther; 1994 Jan; 1(1):13-26. PubMed ID: 7584055
[TBL] [Abstract][Full Text] [Related]
40. Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects.
MacGregor RR
Hum Gene Ther; 2001 Nov; 12(16):2028-9. PubMed ID: 11727736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
